ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Senseonics Holdings Inc

Senseonics Holdings Inc (SENS)

1.13
0.12
(11.88%)
At close: January 26 4:00PM
1.13
0.00
( 0.00% )
After Hours: 7:59PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
0.500.550.650.550.600.0510.00 %2511,4551/24/2025
1.000.200.250.250.2250.0525.00 %1,9515,1371/24/2025
1.500.050.100.050.075-0.01-16.67 %9871,9971/24/2025
2.000.050.050.020.05-0.03-60.00 %594561/24/2025
3.000.050.050.050.050.000.00 %09-

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
0.500.030.050.010.04-0.02-66.67 %47571/24/2025
1.000.100.150.110.125-0.04-26.67 %2207961/24/2025
1.500.400.500.500.45-0.10-16.67 %29471/24/2025
2.000.800.951.200.8750.000.00 %039-
3.001.802.150.001.9750.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HWHHWH International Inc
$ 0.4549
(58.12%)
5.08M
TVGNTevogen Bio Holdings Inc
$ 1.70
(25.93%)
3.78M
TCTMTCTM Kids IT Education Inc
$ 0.4005
(22.89%)
6.9M
LGTYLogility Supply Chain Solutions Inc
$ 13.86
(22.44%)
7.22k
YIBOPlanet Image International Ltd
$ 2.62
(21.86%)
18.74k
ACONAclarion Inc
$ 0.0373
(-32.06%)
56.3M
MVSTMicrovast Holdings Inc
$ 1.91
(-12.39%)
2.53M
ELABPMGC Holdings Inc
$ 2.77
(-10.65%)
612.94k
CGBSCrown LNG Holdings Ltd
$ 0.515
(-9.60%)
360.33k
NITON2OFF Inc
$ 1.11
(-9.02%)
123.79k
ACONAclarion Inc
$ 0.0373
(-32.06%)
56.3M
MULNMullen Automotive Inc
$ 0.533
(20.94%)
22.18M
RIMEAlgorhythm Holdings Inc
$ 0.0352
(-6.88%)
17.87M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.3725
(-2.77%)
6.97M
TCTMTCTM Kids IT Education Inc
$ 0.4005
(22.89%)
6.9M

SENS Discussion

View Posts
stinsmoney stinsmoney 2 days ago
Do I need to buy into this?
๐Ÿ‘๏ธ0
Acme Investments Acme Investments 2 days ago
Wrong again!! Sad!! Lol 😂
๐Ÿ‘๏ธ0
subslover subslover 2 days ago
I'm over 100% on my .52 😁
๐Ÿ‘๏ธ0
subslover subslover 3 days ago
Today is the first close at $1.00 since March 1, 2023😋.
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 3 days ago
aye aye
๐Ÿ‘๏ธ0
subslover subslover 3 days ago
This one is a keeper, buddy!🤣
๐Ÿ‘๏ธ0
subslover subslover 3 days ago
The $1.04 yesterday was the 52-week high. This baby is sitting on the big one, ain't out yet♥️
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 week ago
SENS, new 52 week high
👍 1
PonkenPlonken PonkenPlonken 1 week ago
little dippity
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 week ago
SENS.............................https://stockcharts.com/h-sc/ui?s=SENS&p=W&b=5&g=0&id=p86431144783
👍️ 1 😍 1 🤓 1
subslover subslover 1 week ago
That would be amazing!🥰
👍 1
ollik78 ollik78 1 week ago
Yes Sir 👍
3$ would be nice 
👍️ 1 😷 1
subslover subslover 1 week ago
Stock is looking strong!😷
👍 1
subslover subslover 2 weeks ago
Interesting RANZ. I'm checking them out now and thank you for the heads up! that is very sweet of you🤩
๐Ÿ‘๏ธ0
tw0122 tw0122 2 weeks ago
Thanks what you think about RNAZ some more news should be out soon. Tiny float after RS of course $3.30s
๐Ÿ‘๏ธ0
subslover subslover 2 weeks ago
A slick bunch of insiders running this Company while buying millions of $$ worth of shares all on Form 4's while stating a date for an R/S was gonna be done. We were saying "WHY" would they be buying before a R/S? Another puzzling thing is this stock has been under $1.00 for over a year which is not in compliance with NASDAQ bid rule so that would be a reason to R/S. But no they cancelled the R/S so these guys knew all along there would be no R/S! Slick. The stock is bloated with a very large outstanding and public float so they must have some huge deal in the works, or at least one would think so. This is one is most interesting and will love to see how it plays out
👍️ 2
Invest-in-America Invest-in-America 2 weeks ago
SENS: Once again, that DAZZZLING linguistical WIT, Homeboy!!! (But it took me circa 15-seconds to figure-out your PUNS there!!! )
๐Ÿ‘๏ธ0
tw0122 tw0122 2 weeks ago
It all makes sens to make a few sens here
.82 + 90% 
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 weeks ago
Glucose monitoring. There are at least 5o companies that do this. GCTK has the best device and look what happened to that stock
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 2 weeks ago
SENS: Very SOLID price movement behind this puppy today.
๐Ÿ‘๏ธ0
subslover subslover 2 weeks ago
Your phone calls to management worked!🥰
๐Ÿ‘๏ธ0
subslover subslover 2 weeks ago
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting
GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational, financial and other business updates.

Recent Highlights & Accomplishments

Generated preliminary unaudited fourth quarter revenue of approximately $8.3 million, and preliminary unaudited full year 2024 total revenue of approximately $22.5 million
Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia.
Patient base increased 56% in 2024 over 2023 to approximately 6,000 global patients
Reached a milestone of over a 1,000 annual U.S. Eversense prescribers during 2024
Continued strong interest in Eversense 365, as evidenced by the following early U.S. launch performance indicators: Direct to Consumer (DTC) leads have doubled in Q4 compared to the pre-launch third quarterNew patient shipments of approximately 600 in December were the highest monthly total in the Companyโ€™s historyThe number of patients switching to Eversense from competitive CGMโ€™s has increased 49% since Eversense 365 launch118% increase in patient referrals from physicians since launch
Following recent appreciation in Companyโ€™s share price, determined not to proceed with previously announced Special Meeting of stockholders to consider reverse stock split.
โ€œ2024 was a tremendous year for Senseonics, achieving our long-term goal of commercializing the Eversense 365 product, providing people with diabetes a convenient and accurate solution for monitoring blood glucose for an entire year with a single sensor. Additionally, weโ€™ve strengthened our position in the marketplace through the newly created CGM division of our commercial partner, Ascensia, and our partnership with Mercy health system, targeted to proactively improve health outcomes and decrease overall systemwide costs for people with diabetes,โ€ said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. โ€œPatient and provider leads, conversion rates, and interest from health systems have all increased significantly since the U.S. 365 launch, culminating in the highest number of monthly new patient shipments in December 2024, and we expect to see those numbers continue to accelerate in 2025. We also expect to provide updates on pump-connectivity, additional health care systems and our ex-US launch over the course of the year.โ€

2024 Financial Results

The Company currently expects to report revenues of approximately $8.3 million for the fourth quarter 2024 and full year 2024 total revenue of approximately $22.5 million. Total unaudited operating expenses and associated cash utilization for the fourth quarter 2024 and full year 2024 was consistent with the previously guided range. The Companyโ€™s unaudited balance of cash, cash equivalents and restricted cash as of December 31, 2024, is expected to be approximately $74.9 million. The Company expects to report its full fourth quarter and fiscal year 2024 financial results later this quarter. The preliminary financial results described in this update have not been audited and are subject to adjustment based on the Companyโ€™s completion of year-end financial close processes.

Cancellation of Special Meeting of Stockholders

The Company has determined not to proceed with the Special Meeting, scheduled for January 10, 2025, for the purpose of seeking shareholder approval of a proposed reverse stock split within the range of 25:1 to 50:1. Since announcing the proposed stock split on November 19, 2024 in parallel with the ongoing launch of the 365-day product the Companyโ€™s share price has increased. As of January 7, 2025, proxies had been received from sufficient stockholders to constitute a quorum for the meeting, with a majority of such shares voting in favor of the proposed reverse stock split as of such date. However, after assessing the pricing implications of a reverse split at the lowest end of the proposed range of stock splits, and taking into consideration shareholder feedback regarding conducting a reverse split of at this time, the Company determined not to proceed with the Special Meeting and the proposed reverse stock split.

Considerations for 2025 Growth Outlook

The Company also plans to provide financial guidance for 2025 in conjunction with its reporting of full fiscal year 2024 financial results. The Company currently expects that the 2025 guidance will reflect positive revenue growth in 2025 over 2024, taking into account the following factors, among others: (i) Ascensiaโ€™s completion of financial forecasts for their fiscal year beginning on April 1st, 2025, (ii) plans with respect to spending on the DTC marketing campaign to generate leads, (iii) the status of other sales and marketing initiatives, and (iv) refined visibility of the timeline and specifications for the regulatory submission and the plans for commercial transition to Eversense 365 outside the United States.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 13 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.

About PHC Holdings Corporation

PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Groupโ€™s consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries. www.phchd.com

©2024 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics, including the anticipated level of fourth quarter 2024 and full year 2024 revenue and cash, cash equivalents and restricted cash as of December 31, 2024, and projected 2025 financial performance described in โ€œConsiderations for 2025 Growth Outlook,โ€ statements regarding the expected acceleration of patient and provider leads, conversion rates, and interest from health systems in 2025, statements regarding pump-connectivity, additional health care systems and the Companyโ€™s ex-US launch of the 365-day system, and other statements containing the words "believe," โ€œexpect,โ€ โ€œintend,โ€ โ€œmay,โ€ โ€œprojects,โ€ โ€œwill,โ€ โ€œplanned,โ€ and similar expressions, constitute forward-looking statements within the me
๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 weeks ago
SENS.....................https://stockcharts.com/h-sc/ui?s=SENS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
nbm16yankees nbm16yankees 3 weeks ago
here's the contents of tonight's news release.


Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting
January 08 2025 - 6:12PM

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational, financial and other business updates.

Recent Highlights & Accomplishments

Generated preliminary unaudited fourth quarter revenue of approximately $8.3 million, and preliminary unaudited full year 2024 total revenue of approximately $22.5 million
Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia.
Patient base increased 56% in 2024 over 2023 to approximately 6,000 global patients
Reached a milestone of over a 1,000 annual U.S. Eversense prescribers during 2024
Continued strong interest in Eversense 365, as evidenced by the following early U.S. launch performance indicators:
Direct to Consumer (DTC) leads have doubled in Q4 compared to the pre-launch third quarter
New patient shipments of approximately 600 in December were the highest monthly total in the Companyโ€™s history
The number of patients switching to Eversense from competitive CGMโ€™s has increased 49% since Eversense 365 launch
118% increase in patient referrals from physicians since launch
Following recent appreciation in Companyโ€™s share price, determined not to proceed with previously announced Special Meeting of stockholders to consider reverse stock split.

โ€œ2024 was a tremendous year for Senseonics, achieving our long-term goal of commercializing the Eversense 365 product, providing people with diabetes a convenient and accurate solution for monitoring blood glucose for an entire year with a single sensor. Additionally, weโ€™ve strengthened our position in the marketplace through the newly created CGM division of our commercial partner, Ascensia, and our partnership with Mercy health system, targeted to proactively improve health outcomes and decrease overall systemwide costs for people with diabetes,โ€ said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. โ€œPatient and provider leads, conversion rates, and interest from health systems have all increased significantly since the U.S. 365 launch, culminating in the highest number of monthly new patient shipments in December 2024, and we expect to see those numbers continue to accelerate in 2025. We also expect to provide updates on pump-connectivity, additional health care systems and our ex-US launch over the course of the year.โ€

2024 Financial Results

The Company currently expects to report revenues of approximately $8.3 million for the fourth quarter 2024 and full year 2024 total revenue of approximately $22.5 million. Total unaudited operating expenses and associated cash utilization for the fourth quarter 2024 and full year 2024 was consistent with the previously guided range. The Companyโ€™s unaudited balance of cash, cash equivalents and restricted cash as of December 31, 2024, is expected to be approximately $74.9 million. The Company expects to report its full fourth quarter and fiscal year 2024 financial results later this quarter. The preliminary financial results described in this update have not been audited and are subject to adjustment based on the Companyโ€™s completion of year-end financial close processes.

Cancellation of Special Meeting of Stockholders

The Company has determined not to proceed with the Special Meeting, scheduled for January 10, 2025, for the purpose of seeking shareholder approval of a proposed reverse stock split within the range of 25:1 to 50:1. Since announcing the proposed stock split on November 19, 2024 in parallel with the ongoing launch of the 365-day product the Companyโ€™s share price has increased. As of January 7, 2025, proxies had been received from sufficient stockholders to constitute a quorum for the meeting, with a majority of such shares voting in favor of the proposed reverse stock split as of such date. However, after assessing the pricing implications of a reverse split at the lowest end of the proposed range of stock splits, and taking into consideration shareholder feedback regarding conducting a reverse split of at this time, the Company determined not to proceed with the Special Meeting and the proposed reverse stock split.

Considerations for 2025 Growth Outlook

The Company also plans to provide financial guidance for 2025 in conjunction with its reporting of full fiscal year 2024 financial results. The Company currently expects that the 2025 guidance will reflect positive revenue growth in 2025 over 2024, taking into account the following factors, among others: (i) Ascensiaโ€™s completion of financial forecasts for their fiscal year beginning on April 1st, 2025, (ii) plans with respect to spending on the DTC marketing campaign to generate leads, (iii) the status of other sales and marketing initiatives, and (iv) refined visibility of the timeline and specifications for the regulatory submission and the plans for commercial transition to Eversense 365 outside the United States.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 13 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.

About PHC Holdings Corporation

PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Groupโ€™s consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries. www.phchd.com

©2024 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.
๐Ÿ‘๏ธ0
nbm16yankees nbm16yankees 3 weeks ago
no reverse split. Special meeting cancelled. News out tonight concerning that plus guidance

Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting โ€ข GlobeNewswire Inc. โ€ข 01/08/2025 11:12:09 PM
👍️ 1 🥰 1
1hot toddy 1hot toddy 3 weeks ago
rs could happen anytime, even before meeting
๐Ÿ‘๏ธ0
subslover subslover 4 weeks ago
More insider buy on 12/20 https://www.otcmarkets.com/filing/html?id=18062131&guid=4aY-kqlFPoXNh3h
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 month ago
sens....................https://stockcharts.com/h-sc/ui?s=sens&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 1 month ago
now director buys 300k shares. im calling him up as well today. left message yesterday on cfo phone
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 1 month ago
sent cfo rick a note. saying stock got mojo dont screw it up
๐Ÿ‘๏ธ0
subslover subslover 1 month ago
I'm not a shareholder but it sure sounds like you are. You can give them a piece of your mind but that won't change anything. Most of these public Companies CEO's think they are smarter than everyone else when it comes to running a Company and thinking they know the fundamentals of IR is a grave mistake
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 1 month ago
I looked back in the news and didn't see a nyse notice. I did read that he thinks he can get more exposure if not in pennies. I say you got to crawl, walk, run. At 45 cents we r at the crawl stage. With mojo and good prs with new business stock will get over a buck. I'm going to call on Monday and try to speak with CEO or CFO and knock some sense into them. If we at 75 cents and they do a 25/1
We will be over 17 and cockroaches will pound it down and make a bundle
. Bad guys make alot of money and good guys losing bigtime
๐Ÿ‘๏ธ0
subslover subslover 1 month ago
Not only that but this already bloated outstanding is currently being severely diluted with offerings and PPs Yeah I'm sure these guys have nice contracts to announce after the R/S but like you said why would they buy a shit load of stock now? They sound stupid to me. 🥸Makes no logical sense 🫨
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 1 month ago
why are they screwing everything up in jan? the stock has mojo and when they announce their new clients the stock could hit buck or higher.

you need to tell ceo and cfo both who bought huge amount of shares that if big rs they will pound the stock down and they and shareholders will lose alot of money.

they need to chill out. they are crawling not running yet. these n2ext two months are best in the market
๐Ÿ‘๏ธ0
subslover subslover 1 month ago
Dear Stockholders:
You are cordially invited to a Special Meeting of Stockholders of Senseonics Holdings, Inc., a Delaware corporation. The meeting will be held at 10:00 a.m. Eastern Time on January 10, 2025. The Special Meeting will be a completely virtual meeting of stockholders. Stockholders may participate in the meeting and submit questions electronically during the meeting via live webcast by visiting the virtual meeting platform at www.virtualshareholdermeeting.com/SENS2025SM.
We are holding the meeting for the following purposes, as more fully described in the accompanying proxy statement:
1.
To approve a series of alternate amendments to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock (with a proportionate reduction in the authorized number of shares of common stock) in the range of 1-for-25 to 1-for-50, at any time prior to January 10, 2026, if and as determined by our Board of Directors in its sole discretion (the โ€œReverse Stock Split Proposalโ€); and
?
2.
To transact any other business that may be properly brought before the meeting or any continuation, adjournment or postponement thereof.
?
All of our stockholders of record as of November 18, 2024 are entitled to attend and vote at the meeting and at any adjournment or postponement thereof.
The special meeting will be conducted as a virtual meeting via the internet
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 1 month ago
99000 SHARE BUY $$$$$$$$$$$$
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 1 month ago
WOOOW 115000 SHARE BUY $$$$$$$$$$$$$$$
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 1 month ago
88000 SHARE BUY @.483. CEO AND CFO BUY TON MORE SHARES $$$$$$$$$$$
๐Ÿ‘๏ธ0
subslover subslover 1 month ago
Heavy insider buying.
https://www.otcmarkets.com/filing/html?id=18043213&guid=E3Y-kqbNqZT6Jth
https://www.otcmarkets.com/filing/html?id=18037285&guid=E3Y-kqbNqZT6Jth
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 month ago
SENS........................https://stockcharts.com/h-sc/ui?s=SENS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Monksdream Monksdream 2 months ago
SENS, new 52 week low
๐Ÿ‘๏ธ0
Profit Profit 3 months ago
This is going to get real!
๐Ÿ‘๏ธ0
nbm16yankees nbm16yankees 3 months ago
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
October 10 2024 - 4:10PM
PR Newswire (US)
Print
Share On Facebook

Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older

Commercial launch by Ascensia Diabetes Care underway with a new campaign to highlight the unique benefits of having just one CGM for one full year

GERMANTOWN, Md. and ST. LOUIS, Oct. 10, 2024 /PRNewswire/ -- Senseonics Holdings, Inc. (NYSE American: SENS) ("Senseonics" or the "Company"), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Mercy, a leading healthcare system, today announced that the first commercial patient received the next-generation Eversense® 365 CGM system. This milestone, part of the company's previously announced collaboration with Mercy, marks the world's first commercial use of Eversense 365, the only CGM to provide one-year of accurate monitoring with minimal interruptions.

Mercy (https://www.mercy.net/newsroom/mercy-quick-facts/), one of the 20 largest U.S. health systems and named the top large system in the U.S. for excellent patient experience by NRC Health, serves millions annually with nationally recognized quality care and one of the nationโ€™s largest Accountable Care Organizations. Mercy is a highly integrated, multi-state health care system including more than 50 acute care and specialty (heart, childrenโ€™s, orthopedic and rehab) hospitals, convenient and urgent care locations, imaging centers and pharmacies. Mercy has over 900 physician practice locations and outpatient facilities, more than 4,500 physicians and advanced practitioners and more than 47,000 co-workers serving patients and families across Arkansas, Kansas, Missouri and Oklahoma. Mercy also has clinics, outpatient services and outreach ministries in Arkansas, Louisiana, Mississippi and Texas. (PRNewsfoto/Mercy)
"This is a pivotal moment for people with diabetes..."

This patient and those who follow, along with their doctors, will be able to monitor glucose levels and trends for a full year, with no requirement for additional sensor replacements and only one calibration per week. Eversense 365 offers patients a truly differentiated CGM experience, enabling confident decisions, long-term peace of mind and enhanced quality of life with just one CGM. It also helps people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs that are indicated to last just 10-14 days. Senseonics and Mercy expect this significant breakthrough in diabetes technology and management to improve gylcemic control for patients, reduce distress associated with managing diabetes and lower overall healthcare costs for providers and payers.

"Without the technology, patients deal with constant finger pricks to test their glucose or have sensors that need to be replaced every few days," said Dr. Jeff Ciaramita, Mercy's president of specialty service lines. "This is a pivotal moment for people with diabetes because this groundbreaking technology allows patients a more convenient and reliable way to manage their condition for an entire year with a single sensor. As Mercy strives to make care easy for our patients, what better way than to be the first in the world to offer Eversense 365."

Eversense 365 was approved by the U.S. Food and Drug Administration last month. The commercial launch, which has now begun, is being managed by Senseonics global commercial partner, Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation (TSE 6523). Mercy serves 3 million patients annually and expects that approximately 30,000 of Mercy's patients could benefit from a CGM system.

"We are thrilled to see the successful first commercial insertion of the Eversense 365 CGM system at Mercy," said Francine Kaufman, M.D. Senseonics' chief medical officer. "Eversense 365 addresses many of the challenges that patients experience with traditional, short-term CGMs and we are excited to see the real-world benefit it can have as it is rolled out to patients across the U.S. We expect that health systems across the country will recognize the benefits that Mercy has embraced and can adopt Eversense 365 towards enhancing the quality of care while reducing the cost of care. Our goal is to make this life-changing technology accessible to as many patients as possible through collaborations with forward-thinking health care leaders such as Mercy."

"This long-term monitoring solution empowers patients with real-time data and enables our clinicians to deliver proactive, personalized care, ultimately leading to better health and quality of life for those we serve," Dr. Ciaramita said. "By adopting Eversense 365, we're enhancing our commitment to value-based care ?driving to improve patient outcomes while reducing overall health care costs."

To learn more about Eversense 365 and for additional information about when the system will be available, go to www.eversensecgm.com. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at https://provider.eversensecgm.com/contact-us/. Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.

About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com

About PHC Holdings Corporation

PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com

©2024 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

About Mercy

Mercy, one of the 20 largest U.S. health systems and named the top large system in the U.S. for excellent patient experience by NRC Health, serves millions annually with nationally recognized care and one of the nation's largest and highest performing Accountable Care Organizations in quality and cost. Mercy is a highly integrated, multi-state health care system including more than 50 acute care and specialty (heart, children's, orthopedic and rehab) hospitals, convenient and urgent care locations, imaging centers and pharmacies. Mercy has over 900 physician practice locations and outpatient facilities, more than 4,500 physicians and advanced practitioners and 50,000 co-workers serving patients and families across Arkansas, Kansas, Missouri and Oklahoma. Mercy also has clinics, outpatient services and outreach ministries in Arkansas, Louisiana, Mississippi and Texas. In fiscal year 2023 alone, Mercy provided more than half a billion dollars of free care and other community benefits, including traditional charity care and unreimbursed Medicaid.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements regarding plans and timing for the commercial launch of the 356-day system, statements regarding the attributes experienced by people with diabetes and differentiating the system from short-term CGM, and statements regarding the experience, potential results and decisions of health care systems, and other statements containing the words "believe," "expect," "intend," "may," "projects," "will," "planned," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the execution of the independent business unit of Ascensia Diabetes Care, the Company's commercialization partner for Eversense, and other commercial initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration and roll-out of new technology and solutions, uncertainties inherent in finalizing integration and commercial terms and coordinations with health systems and other new collaboration partners and third parties, uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product, uncertainties relating to the current economic environment and such other factors as are set forth in the risk factors detailed in Senseonics' Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 and Senseonics' other filings with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof.

Senseonics Logo

View original content to download multimedia:https://www.prnewswire.com/news-releases/mercy-places-first-commercial-eversense-365-the-worlds-first-and-only-365-day-continuous-glucose-monitor-302273383.html

SOURCE Mercy
๐Ÿ‘๏ธ0
glenn1919 glenn1919 4 months ago
SENS.......................................https://stockcharts.com/h-sc/ui?s=SENS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
SENS new 52 week low
๐Ÿ‘๏ธ0
antman antman 9 months ago
So I guess they are taking this one down to zero now.too?
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
Wall Street Millennial
๐Ÿ‘๏ธ0
$5.95akadawson-m $5.95akadawson-m 1 year ago
saw you on the Ballard and FCEL board with the identical message. What's UP?
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
SENS new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
SENS new 52 week low
๐Ÿ‘๏ธ0